Reck M - Search Results

1

Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?

Popat S, Grohé C, Corral J, Reck M, Novello S, Gottfried M, Radonjic D, Kaiser R. Popat S, et al. Among authors: reck m. Lung Cancer. 2020 Jun;144:76-84. doi: 10.1016/j.lungcan.2020.04.009. Epub 2020 Apr 20. Lung Cancer. 2020. PMID: 32387684 Free article. Review.

2

Carboplatin in small cell lung cancer.

Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L. Gatzemeier U, et al. Among authors: reck m. Semin Oncol. 1991 Feb;18(1 Suppl 2):8-16. Semin Oncol. 1991. PMID: 1846981 Clinical Trial.

3

Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study.

Reck M, Jagos U, Grunwald F, Kaukel E, Koschel G, von Pawel J, Hessler S, Gatzemeier U. Reck M, et al. Lung Cancer. 2003 Jan;39(1):63-9. doi: 10.1016/s0169-5002(02)00383-5. Lung Cancer. 2003. PMID: 12499096 Clinical Trial.

4

Chemotherapy in stage-IV NSCLC.

Reck M, Gatzemeier U. Reck M, et al. Lung Cancer. 2004 Aug;45 Suppl 2:S217-22. doi: 10.1016/j.lungcan.2004.07.972. Lung Cancer. 2004. PMID: 15552802 Review.

5

Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.

Reck M, Groth G, Buchholz E, Goetz E, Gatzemeier U, Manegold C. Reck M, et al. Lung Cancer. 2005 Jun;48(3):409-13. doi: 10.1016/j.lungcan.2004.11.013. Epub 2005 Jan 23. Lung Cancer. 2005. PMID: 15893010 Clinical Trial.

6

Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.

Reck M, Gatzemeier U. Reck M, et al. Lung Cancer. 2005 Oct;50(1):107-14. doi: 10.1016/j.lungcan.2005.05.006. Lung Cancer. 2005. PMID: 15985306 Clinical Trial.

7

Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.

Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U. Reck M, et al. Lung Cancer. 2006 Jul;53(1):67-75. doi: 10.1016/j.lungcan.2006.04.001. Epub 2006 May 19. Lung Cancer. 2006. PMID: 16713013 Clinical Trial.

8

Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.

Reck M, Buchholz E, Romer KS, Krutzfeldt K, Gatzemeier U, Manegold C. Reck M, et al. Clin Lung Cancer. 2006 May;7(6):406-11. doi: 10.3816/clc.2006.n.025. Clin Lung Cancer. 2006. PMID: 16800967 Clinical Trial.

9

Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.

Reck M, Crinò L. Reck M, et al. Lung Cancer. 2009 Jan;63(1):1-9. doi: 10.1016/j.lungcan.2008.05.015. Epub 2008 Jun 25. Lung Cancer. 2009. PMID: 18579254 Review.

10

Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.

Reck M, Macha HN, Del Barco S, Cornes P, Vaissière N, Morand M, Riggi M, Abratt R. Reck M, et al. Lung Cancer. 2009 Jun;64(3):319-25. doi: 10.1016/j.lungcan.2008.10.014. Epub 2008 Dec 17. Lung Cancer. 2009. PMID: 19095327 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

533 results

Search Page

Filters